Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00411892
Recruitment Status : Terminated (See termination reason in detailed description)
First Posted : December 15, 2006
Last Update Posted : March 1, 2017
Information provided by (Responsible Party):
Novo Nordisk A/S

December 14, 2006
December 15, 2006
March 1, 2017
November 29, 2006
March 18, 2008   (Final data collection date for primary outcome measure)
HbA1c change from baseline [ Time Frame: After 26 weeks of treatment ]
HbA1c change from baseline after 26 weeks of treatment
Complete list of historical versions of study NCT00411892 on Archive Site
  • Fasting plasma glucose [ Time Frame: after 26 weeks of treatment ]
  • Lipid profiles [ Time Frame: after 26 weeks of treatment ]
  • Frequency of hypoglycaemic episodes [ Time Frame: after 26 weeks of treatment ]
  • Glucose profiles [ Time Frame: at pre- and post meals, bedtime and 3:00 am ]
  • Change in body weight [ Time Frame: after 26 weeks of treatment ]
  • Fasting plasma glucose
  • Lipid profiles
  • frequency of hypoglycaemic episodes after 26 weeks of treatment
  • Glucose profiles
  • Change in body weight
Not Provided
Not Provided
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
This trial is conducted in the United States of America (USA). This trial will compare the changes in HbA1c after 26 weeks of inhaled insulin and pioglitazone combination therapy versus pioglitazone treatment alone.
The decision to discontinue the development of AERx® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Diabetes
  • Diabetes Mellitus, Type 2
  • Drug: pioglitazone
    Tablets, 45 mg/day.
  • Drug: inhaled human insulin
    Treat-to-target dose titration scheme, inhalation.
    Other Name: NN1998
  • Experimental: A
    • Drug: pioglitazone
    • Drug: inhaled human insulin
  • Active Comparator: B
    Intervention: Drug: pioglitazone
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
March 18, 2008
March 18, 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Type 2 diabetes
  • Current treatment with oral antidiabetes drugs (OADs) for at least 2 months
  • HbA1c between 7.0-11.0% if on OAD monotherapy
  • HbA1c between 7.0-10.0% if on OAD combination therapy
  • BMI less than or equal to 40 kg/m2

Exclusion Criteria:

  • Current regular smoking or regular smoking within the last 6 months
  • Current acute or chronic pulmonary disease (except for asthma)
  • Proliferative retinopathy requiring treatment
  • Clinically significant disease history including kidney or liver disease, or heart disease which limits physical activity or results in discomfort with physical activity
  • Pregnancy
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Novo Nordisk A/S
Novo Nordisk A/S
Not Provided
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
Novo Nordisk A/S
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP